Status:
COMPLETED
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
Lead Sponsor:
Watson Pharmaceuticals
Conditions:
Anemia, Iron-Deficiency
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are rec...
Eligibility Criteria
Inclusion
- Moderate to severe anemia
- Iron deficiency
- Moderate to severe chronic kidney disease
- Receiving therapy with erythropoietic agent
Exclusion
- Receiving dialysis
- Known sensitivity to Ferrlecit® or any of its components
- Clinically unstable
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00224042
Start Date
April 1 2003
Last Update
March 29 2012
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Tucson, Arizona, United States
3
Los Angeles, California, United States
4
Palo Alto, California, United States